Alexey Tryakin
Overview
Explore the profile of Alexey Tryakin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ivanov M, Lebedeva A, Belova E, Grigoreva T, Veselovsky E, Kavun A, et al.
J Clin Lab Anal
. 2025 Mar;
:e70008.
PMID: 40056420
Background: Next-generation sequencing (NGS) is increasingly integrated into cancer patient management, necessitating cost-effective, reliable tests for companion diagnostics. We present the validation of the Solo-test Driver panel, a custom NGS...
2.
Kravchuk D, Lebedeva A, Kuznetsova O, Kavun A, Taraskina A, Belova E, et al.
Front Immunol
. 2025 Feb;
16:1492296.
PMID: 39975556
Microsatellite instability (MSI) is a widely studied molecular signature, which is associated with long-term benefit in patients treated with immune checkpoint inhibitor therapy. This approach has been proven to be...
3.
Veselovsky E, Lebedeva A, Kuznetsova O, Kravchuk D, Belova E, Taraskina A, et al.
Sci Rep
. 2024 Oct;
14(1):23454.
PMID: 39379462
Analysis of serial liquid biopsy (LB) samples has been found to be a promising approach for the monitoring of tumor dynamics in the course of therapy for patients with colorectal...
4.
Babayan A, Ledin E, Lebedeva A, Kuznetsova O, Kravchuk D, Grigoreva T, et al.
Immunotherapy
. 2024 Jul;
16(13):853-858.
PMID: 39041702
Microsatellite instability (MSI) is an important biomarker in cancer. While routine methods can detect MSI in certain tumor types, in other tumor types the results may be incorrect due to...
5.
Lebedeva A, Kuznetsova O, Ivanov M, Kavun A, Veselovsky E, Belova E, et al.
Heliyon
. 2024 May;
10(9):e30303.
PMID: 38707351
Genomic profiling, or molecular profiling of the tumor, is becoming a key component of therapeutic decision making in clinical oncology, and is typically carried out via next generation sequencing. However,...
6.
Kuznetsova O, Fedyanin M, Zavalishina L, Moskvina L, Kuznetsova O, Lebedeva A, et al.
World J Gastrointest Oncol
. 2024 Apr;
16(3):643-652.
PMID: 38577454
Colorectal cancer (CRC) represents a molecularly heterogeneous disease and one of the most frequent causes of cancer-related death worldwide. The traditional classification of CRC is based on pathomorphological and molecular...
7.
Buhrer E, DHaese D, Daugaard G, de Wit R, Albany C, Tryakin A, et al.
Eur J Cancer
. 2024 Apr;
202:114042.
PMID: 38564927
Aims: To resolve the ongoing controversy surrounding the impact of teratoma (TER) in the primary among patients with metastatic testicular non-seminomatous germ-cell tumours (NSGCT). Patients And Methods: Using the International...
8.
Rastogi P, OShaughnessy J, Martin M, Boyle F, Cortes J, Rugo H, et al.
J Clin Oncol
. 2024 Jan;
42(9):987-993.
PMID: 38194616
JCO Two years of adjuvant abemaciclib combined with endocrine therapy (ET) resulted in a significant improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) that persisted beyond the...
9.
Polyanskaya E, Lebedeva A, Kuznetsova O, Belova E, Kavun A, Ivanov M, et al.
Front Oncol
. 2023 Nov;
13:1245547.
PMID: 38023256
Colorectal cancer (CRC) is currently one of the most common tumor types diagnosed worldwide. In the early stages, the disease responds well to surgical and chemotherapeutic treatment, but in the...
10.
Lauritsen J, Sauve N, Tryakin A, Jiang D, Huddart R, Heng D, et al.
Br J Cancer
. 2023 Sep;
129(11):1759-1765.
PMID: 37777577
Background: Active surveillance after orchiectomy is the preferred management in clinical stage I (CSI) germ-cell tumours (GCT) associated with a 15 to 30% relapse rate. Patients And Methods: In the...